| GPOS |
GPOS |
85%
|
During the fourth quarter of 2022, we began contracting directly with intermediaries such as GPOs. |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
lization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing facilities are subject to inspection before the F… |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: Reciprocal relationship from TMO grap… |
| ARX-LLC |
ARX-LLC |
62%
|
d December 31, 2025 and 2024 Product Revenue, Net 121 Table of Contents Commercial sales of IGALMI ® launched in July 2022. As part of the Company’s Reprioritization, the IGALMI ® commercial team shi… |
| BIOXCEL-HOLDINGS-INC |
BIOXCEL-HOLDINGS-INC |
62%
|
. Our ability to accurately forecast demand for IGALMI ® could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by comp… |
| BIOXCEL-LLC |
BIOXCEL-LLC |
62%
|
efit or disclosed to us confidential information of third parties. As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotech… |
| BIOXCEL-LLC-BIOXCEL-LLC |
BIOXCEL-LLC-BIOXCEL-LLC |
62%
|
n us and BioXcel LLC. BioXcel LLC may experience challenges with the acquisition, development, enhancement, or deployment of technology necessary for EvolverAI. We may face similar challenges with ot… |
| CANACCORD-GENUITY-LLC |
CANACCORD-GENUITY-LLC |
62%
|
impact on our liquidity and future funding requirements are uncertain as of the filing date of this Annual Report on Form 10-K. We will need substantial additional funding, and if we are unable to ra… |
| COMPANY-KRISHNAN-NANDABALAN-PH-D-INVENIAI-LLC |
COMPANY-KRISHNAN-NANDABALAN-PH-D-INVENIAI-LLC |
62%
|
. Our ability to accurately forecast demand for IGALMI ® could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by comp… |
| DERIVATIVE-LIABILITY-ARMISTICE-CAPITAL-MASTER-FU |
DERIVATIVE-LIABILITY-ARMISTICE-CAPITAL-MASTER-FU |
62%
|
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last … |
| DERIVATIVE-LIABILITY-INTRACOASTAL-CAPITAL-LLC |
DERIVATIVE-LIABILITY-INTRACOASTAL-CAPITAL-LLC |
62%
|
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last … |
| EQUITY-ARMISTICE-CAPITAL-MASTER-FUND-LTD |
EQUITY-ARMISTICE-CAPITAL-MASTER-FUND-LTD |
62%
|
e will be determined by the administrator of the ESPP and, for purposes of the Section 423 Component, shall not be less than 85 % of the fair value of a share on the first trading day or on the last … |
| INVEA-THERAPEUTICS-INC |
INVEA-THERAPEUTICS-INC |
62%
|
. Our ability to accurately forecast demand for IGALMI ® could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by comp… |
| LEARNING-RESOURCES-INC |
LEARNING-RESOURCES-INC |
62%
|
I® is listed in the Orange Book and is not currently a generic, biosimilar, or orphan drug, we may be subject to these duties to the extent any portion of IGALMI® or its active pharmaceutical ingredi… |
